Information Provided By:
Fly News Breaks for February 26, 2016
CLDX
Feb 26, 2016 | 08:19 EDT
Cantor says that Celldex's near-term outlook is positive, since its varlilumab drug is moving into Phase II trials and final data will soon be available for its Rintego drug. The firm adds that the company has "a growing pipeline and cash runway through 2017." It keeps a Buy rating on the shares.
News For CLDX From the Last 2 Days
There are no results for your query CLDX